Ключевые слова:
семаглутид, GLP-1, диабет 2 типа, ожирение, щитовидная железаБиблиографические ссылки
Catalin Feier et al., “Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review,” International Journal of Molecular Sciences, vol. 25, no. 8, April 2024, pp. 4346. https://doi.org/10.3390/ ijms25084346
Manoj Kumar Mahapatra, Muthukkumar Karuppasamy, Biswa Mohan Sahoo, “Semaglutide, a Glucagon like Peptide-1 Receptor Agonist with Cardiovascular Benefits for Management of Type 2 Diabetes,” Reviews in Endocrine and Metabolic Disorders, vol. 23, no. 3, May 2022, pp. 321–339. https:// doi.org/10.1007/s11154-021-09694-1
Anne Lautenbach et al., “The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery – Retrospective Analysis,” Obesity Surgery, vol. 32, no. 10, October 2022, pp. 3208–18. https://doi.org/10.1007/s11695-022-06121-9
Steven E. Kahn et al., “Effect of Semaglutide on Regression and Progression of Glycemia in People with Overweight or Obesity Without Diabetes in the SELECT Trial,” Diabetes Care, vol. 47, no. 4, April 2024, pp. 1350–59. https://doi.org/10.2337/dc24-0091
Gurdeep Singh, Mathew Kuthanur, Meghan Bjaime-Evans, “Wegovy (Semaglutide): A New Wei-ght Loss Drug for Chronic Weight Management,” Journal of Investigative Medicine, vol. 70, no. 1, January–February 2022, pp. 5–13. https://doi.org/10.11 36/jim-2021-001592
Ariana M. Chao et al., “Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations,” Drug Design, Development and Therapy, vol. 16, 2022, pp. 4449–60. https://doi.org/10.2147 /DDDT.S384616
Matthew J. Armstrong et al., “Similar Weight Loss with Semaglutide Regardless of Diabetes and Cardiometabolic Risk Parameters in Individuals with Metabolic Dysfunction–associated Steatotic Liver Disease: Post Hoc Analysis of Three Randomised Controlled Trials,” Diabetes, Obesity and Metabolism, vol. 27, no. 2, February 2025, pp. 710–18. https://doi.org/10.1111/dom.15085
Anıl Cengiz, Calvin C. Wu, San Lo Dew, “Alternative Dosing Regimens of GLP-1 Receptor Agonists May Reduce Costs and Maintain Weight Loss Efficacy,” Diabetes, Obesity and Metabolism, vol. 27, no. 5, May 2023, pp. 2251–58. https://doi.org/10.11 11/dom.16292
William Powell et al., “Medications and Conditions Associated with Weight Loss in Patients Prescribed Semaglutide Based on Real-world Data,” Obesity, vol. 31, no. 10, October 2023, pp. 2482–92. https://doi.org/10.1002/oby.23889
Mark M. Smits, Daniel H. Van Raalte, “Safety of Semaglutide,” Frontiers in Endocrinology, vol. 12, 2021, article 645653. https://doi.org/10. 3389/fendo.2021.645653